IMUC in the News
Proactive Investors article: ImmunoCellular Therapeutics armed with platform to “effectively eradicate” cancer.
ImmunoCellular selected by the Society for Immunotherapy of Cancer (SITC) to present results of Phase I study at the 27th Annual Meeting:
November 14, 2012 - ImmunoCellular Therapeutics fully funded to end of Phase II trials
July 19, 2012 - IMUC rings the opening bell at the New York Stock Exchange
CBS - June 7th 2011 - Vaccine for brain tumor
ABC 7 - Feb 14th 2011 - Vaccine may give brain cancer patients time